[1］John R,White Jr.The pharmacological reduction of blood glucose in patients with type 2 diabetes melitus［J］.Clinical Diabetes,1998,16:2. [2］Fuhlendorff J,Rorsman P,Kofod H et al.Stimulation of insulin release by repaglinide and glibenclamide involves both common and diatinet processer［J］.Diabetes,1998,47(3):345. [3］Owens DR.Repaglinide-prandial glucose regulator:a new class of oral antidiabetic drugs［J］.Diabet Med,1998,15(4):S28. [4］Hatorp V,Huang WC,Strang P.Rapaglinide pharmcokinetics in healthy young adult and elderly subjects［J］.Clin Ther，1999，21(4):702. [5］Oliver S,Ahmad S,Hatorp V. Pharmcokinetics and bioavailabilit of repaglinide,a new OHA for patients with NIDDM［J］.Diabetologia，1997,40(Suppl 1):A320. [6］Hatorp V,Huang WC,Strang P. Pharmcokinetics profiles of repaglinide in elderly subjects with type 2 diabetes［J］.J Clin Endocrinol Metab,1999,84(4):1475. [7］Hatorp V,Walther KH,Christensen MS,et al.Single-dose pharmcokinetics of repaglinide in subjects with chronic liver disease［J］.J Clin Pharmacol，2000,40(2):142. [8］Marbury TC,Ruckle JL,Hatorp V ,et al. Pharmcokinetics of repaglinide in subjects with renal impairment［J］.Clin Pharmacol Ther，2000,67(1):7. [9］Hatorp V,Thomsen MS. Drug interaction studies with repaglinide: repaglinide on digoxin or theophylline pharmcokinetics and cimetidine on repaglinide pharmcokinetics［J］.J Clin Pharmacol，2000,40(2):184. [10］Moses R,Slobodniuk R,Boyages S,et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes［J］.Diabetes Care,1999,22(1):119. [11］Owens DR.Repaglinide:a new short- acting insulinotropic agent for the treatment of type 2 diabetes［J］.Eur J Clin Invest,1999,29(Suppl 2):30.